Physician profile
Heather M Larson
NPI 1003249269
$13,292.77
in general payments reported to CMS, 2019-2025
34 companies · $3,919 in 2025
The $3,919 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $2,277 · 2023: $2,755 · 2024: $3,133 · 2025: $3,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,787 · Education: $19.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,786.95 |
| Education | $19.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,546.62 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,993.93 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $1,536.78 | 2021-2025 | |
| Janssen Biotech, INC. | $1,516.40 | 2021-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,335.22 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $984.53 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $473.62 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $441.01 | 2023-2025 | Omvoh, Zepbound, Mounjaro |
| Ironwood Pharmaceuticals, INC | $290.69 | 2021-2024 | Linzess |
| Genzyme Corporation | $275.57 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $253.76 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $216.98 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $206.96 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $173.28 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $162.81 | 2021-2025 | Suflave, Sutab |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $108.06 | 2021-2025 | Rebyota, Clenpiq |
| Merck Sharp & Dohme LLC | $87.09 | 2021-2023 | Dificid |
| Exact Sciences Corporation | $74.57 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $71.98 | 2022-2025 | Wegovy |
| Aimmune Therapeutics, INC. | $61.47 | 2024-2025 | Vowst |
| Gilead Sciences, INC. | $60.71 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $59.48 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.98 | 2023 | Cyltezo |
| Boston Scientific Corporation | $43.22 | 2023 | Watchman Access System |
| Ipsen Biopharmaceuticals, INC | $43.07 | 2024-2025 | Iqirvo |
| Sandoz INC. | $37.63 | 2023 | Hyrimoz |
| Redhill Biopharma INC. | $37.31 | 2021 | |
| Alfasigma USA, INC. | $27.97 | 2021 | |
| Amgen INC. | $26.62 | 2023 | Avsola, Amjevita |
| Blueprint Medicines Corporation | $24.09 | 2025 | Ayvakit |
| Daiichi Sankyo INC. | $24.06 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.72 | 2025 | |
| Madrigal Pharmaceuticals | $15.63 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $14.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.